R&D pipeline – Talk Bio

GSK Appoints Luke Miels as New CEO, Succeeding Emma Walmsley on Jan. 1, 2026

4 weeks ago talkbio0Tagged Appointments, CEO, Emma Walmsley, Leadership Transition, Luke Miels, R&D pipeline, SmithKline Beecham, specialty medicines, Vaccines

GSK; Luke Miels; Emma Walmsley; CEO appointment; pharmaceuticals; leadership transition; specialty medicines; vaccines; R&D pipeline

Novo Nordisk’s Pipeline Cull Prompts Hopes of Strategic Shift

3 months ago talkbio0Tagged competition, GLP-1/GIP co-agonist, Leadership Change, Market, Nordisk, Obesity, pipeline cull, R&D pipeline, semaglutide, strategic shift, Wegovy

Novo Nordisk; pipeline cull; GLP-1/GIP co-agonist; obesity drugs; leadership change; strategic shift; semaglutide; Wegovy; R&D pipeline; market competition

BioMarin Drops Preclinical PKU Drug Once Seen as Potential Palynziq Successor

3 months ago talkbio0Tagged BioMarin, Drug Development, Immunogenicity (package insert), Palynziq, Phenylketonurias, R&D pipeline

BioMarin; PKU; Palynziq; BMN 390; drug development; R&D pipeline; immunogenicity

Lexicon Pharmaceuticals Shifts Focus to Clinical Development Following Zynquista Setbacks

11 months ago talkbio0Tagged (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol, Clinical Development, lexicon, LX9211, LX9851, R&D pipeline, restructuring, United States Food and Drug Administration, Zynquista

Lexicon Pharmaceuticals, Zynquista, FDA, Clinical Development, Restructuring, R&D Pipeline, LX9211, Sotagliflozin, LX9851